Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways

Thrombosis and Haemostasis

Volumn 110, Issue 6, 2013, Pages 1223-1231

  Braun, Oscar Ö ^a   Angiolillo, Dominick J ^b   Ferreiro, Jose L ^c   Jakubowski, Joseph A ^d   Winters, Kenneth J ^d   Effron, Mark B ^d   Duvvuru, Suman ^d   Costigan, Timothy M ^d   Sundseth, Scott S ^e   Walker, Joseph R ^f   Saucedo, Jorge F ^g   Kleiman, Neal S ^h   Varenhorst, Christoph ⁱ  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^d ELI LILLY AND COMPANY   (United States)

^e Cabernet Pharmaceuticals   (United States)

^f DAIICHI SANKYO INC   (United States)

^g NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^h HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

ⁱ UPPSALA UNIVERSITY   (Sweden)

Author keywords

ABCB1; Clopidogrel; CYP2C19; Platelet function; PON1; Prasugrel

Indexed keywords

ACETYLSALICYLIC ACID; ARYLDIALKYLPHOSPHATASE 1; CLOPIDOGREL; CYTOCHROME P450 2C19; MULTIDRUG RESISTANCE PROTEIN 1; PLACEBO; PRASUGREL; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ADULT; AGED; ALLELE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METABOLITE; MULTICENTER STUDY (TOPIC); PHARMACODYNAMICS; PLATELET REACTIVITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); THROMBOCYTE AGGREGATION INHIBITION;

ABCB1; CLOPIDOGREL; CYP2C19; PLATELET FUNCTION; PON1; PRASUGREL;

AGED; ALLELES; ARYL HYDROCARBON HYDROXYLASES; ARYLDIALKYLPHOSPHATASE; BIOTRANSFORMATION; BLOOD PLATELETS; CELL ADHESION MOLECULES; CELLS, CULTURED; CORONARY ARTERY DISEASE; FEMALE; HUMANS; MALE; MICROFILAMENT PROTEINS; MIDDLE AGED; P-GLYCOPROTEIN; PHOSPHOPROTEINS; PIPERAZINES; PLATELET ACTIVATION; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; PYRIDINES; RECEPTORS, PURINERGIC P2Y12; THIOPHENES; TICLOPIDINE;

EID: 84888407930     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-03-0263     Document Type: Article

References (37)

1. Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J 2012; 33: 2569-2619.
2. Bertrand ME, Rupprecht HJ, Urban P, et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000; 102: 624-629.
3. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation 2002; 106: 1893-1900.
4. Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 2999-3054.
5. Gurbel PA, Tantry US. Clopidogrel resistance? Thromb Res 2007; 120: 311-321.
6. Taubert D, Von Beckerath N, Grimberg G, et al. Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther 2006; 80: 486-501.
7. Savi P, Combalbert J, Gaich C, et al. The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thromb Haemost 1994; 72: 313-317.
8. Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000; 84: 891-896.
9. Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006; 108: 2244-2247.
10. Rehmel JL, Eckstein JA, Farid NA, et al. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metab Dispos 2006; 34: 600-607.
11. Brandt JT, Payne CD, Wiviott SD, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 2007; 153: 66. e9-16.
12. Varenhorst C, James S, Erlinge D, et al. Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. Eur Heart J 2009; 30: 1744-1752.
13. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-362.
14. Wallentin L, James S, Storey RF, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 2010; 376: 1320-1328.
15. Sibbing D, Koch W, Gebhard D, et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 2010; 121: 512-518.
16. Cuisset T, Loosveld M, Morange PE, et al. CYP2C19*2 and *17 Alleles Have a Significant Impact on Platelet Response and Bleeding Risk in Patients Treated With Prasugrel After Acute Coronary Syndrome. JACC Cardiovasc Interv 2012; 5: 1280-1287.
17. Grosdidier C, Quilici J, Loosveld M, et al. Effect of CYP2C19*2 and *17 Genetic Variants on Platelet Response to Clopidogrel and Prasugrel Maintenance Dose and Relation to Bleeding Complications. Am J Cardiol 2013; 111: 985-990.
18. Mega JL, Close SL, Wiviott SD, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet 2010; 376: 1312-1319.
19. Bouman HJ, Schomig E, van Werkum JW, et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med 2011; 17: 110-116.
20. Angiolillo DJ, Saucedo JF, Deraad R, et al. Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. J Am Coll Cardiol 2010; 56: 1017-1023.
21. Wallentin L, Varenhorst C, James S, et al. Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J 2008; 29: 21-30.
22. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007; 116: 496-526.
23. Daly TM, Dumaual CM, Miao X, et al. Multiplex assay for comprehensive genotyping of genes involved in drug metabolism, excretion, and transport. Clin Chem 2007; 53: 1222-1230.
24. Aleil B, Ravanat C, Cazenave JP, et al. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 2005; 3: 85-92.
25. Myrand SP, Sekiguchi K, Man MZ, et al. Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first-and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations. Clin Pharmacol Ther 2008; 84: 347-361.
26. Center for Disease Control. U. S. Genome Variation Estimates: PON1 Allele and Genotype Frequencies. Available at: http://www. cdc. gov/genomics/population/genvar/frequencies/PON1. htm. 2013. Accessed January 31, 2013.
27. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-362.
28. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 2009; 119: 2553-2560.
29. Frere C, Cuisset T, Gaborit B, et al. The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome. J Thromb Haemost 2009; 7: 1409-1411.
30. Gurbel PA, Shuldiner AR, Bliden KP, et al. The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy. Am Heart J 2011; 161: 598-604.
31. Bauer T, Bouman HJ, van Werkum JW, et al. Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. Br Med J 2011; 343: d4588.
32. Leschziner GD, Andrew T, Pirmohamed M, et al. ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. Pharmacogenomics J 2007; 7: 154-179.
33. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360: 363-375.
34. Sibbing D, Koch W, Massberg S, et al. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. Eur Heart J 2011; 32: 1605-1613.
35. Lewis JP, Fisch AS, Ryan K, et al. Paraoxonase 1 (PON1) gene variants are not associated with clopidogrel response. Clin Pharmacol Ther 2011; 90: 568-574.
36. Dansette PM, Rosi J, Bertho G, et al. Paraoxonase-1 and clopidogrel efficacy. Nat Med 2011; 17: 1040-1041.
37. Reny JL, Combescure C, Daali Y, et al. Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: a systematic review and meta-analysis. J Thromb Haemost 2012; 10: 1242-1251.